

PHARMANUTRA: THE GROWTH TREND CONTINUES IN THE FIRST 9 MONTHS OF 2018 SALES ABROAD EXCEED SALES IN ITALY

Pisa, 21 November, 2018 - [PharmaNutra S.p.A.](#), a pharmaceutical company that leads the market in the iron-based nutritional supplements sector, listed on the AIM Market Italy, is pleased to report the significant sales results obtained once again in the first 9 months of 2018.

Specifically, as already noted during the first half of the year, the company continues to grow at international level, where PharmaNutra continues to record impressive sales volumes. Forecasts for volumes indicate that by the end of the year, the company will have sold over six million units; approximately 58% of these sales are expected to be recorded on foreign markets (sales by volume).

The international figures represent an essential driver for growth, confirming the popularity of the Group's products also outside of Italy.

Roberto Lacorte, Vice President of PharmaNutra, explains: *“The figures registered by the Group are a source of strong motivation in all directions, but we are especially proud of the results achieved on foreign markets. One of the aims we set ourselves after listing was to boost our international presence, and we are succeeding in this. These figures, as well as reassuring us and confirming the interest in our products, also provide objective proof of the efficacy of our patented Sucrosomial® Technology, and represent an essential driver of growth for the Group”.*

At international level, PharmaNutra has recently signed a partnership agreement with the Swiss company Fresenius Kabi Switzerland for the distribution on the Swiss market of two Sucrosomial® Iron products from the start of 2019, and other two products to be launched by the end of 2020. This is just the latest agreement, following on from the recent partnerships established for the distribution of Sucrosomial® Iron products with Al-Esraa Pharmaceutical Optima for the Egyptian market, and Pharmapoint SA, a Pelion Healthcare Group company, which will be exclusive distributor for Poland of the products in the SiderAL® line.

PharmaNutra S.p.A.

Founded and guided by President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003 that develops unique nutraceutical supplements and innovative nutritional devices, taking care of the entire production process, from the proprietary raw materials to the finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 79 of them published with more than 5000 patients treated. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com